人体生长荷尔蒙市场规模、份额和成长分析（按产品、应用、通路和地区划分）－2026-2033年产业预测

预计到 2024 年，全球人体生长荷尔蒙市场规模将达到 71 亿美元，到 2025 年将达到 79.7 亿美元，到 2033 年将达到 201.7 亿美元，在预测期（2026-2033 年）内，复合年增长率为 12.3%。

全球人体生长荷尔蒙市场持续稳定成长，主要得益于生长激素缺乏症治疗临床指引的进步以及重组荷尔蒙疗法的创新。治疗途径的改善和人们对生长激素缺乏症认识的提高进一步推动了这一增长。各国政府和卫生组织正透过宣传活动促进早期发现，并强调解决此疾病的重要性。顺应新兴市场趋势，主要企业正加大研发投入，致力于开发副作用较少的生长激素。此外，人体生长荷尔蒙在组织再生和细胞分裂等过程中发挥着至关重要的作用，凸显了其在人类整体生长和健康中的重要性，因此各方正齐心协力，努力有效治疗激素相关疾病。

全球人体生长荷尔蒙市场驱动因素

透纳氏症和生长激素缺乏症等异常生长模式的发生率不断上升，显着影响全球对人体生长荷尔蒙产品的需求。随着人们对这些疾病的认识不断提高，早期诊断也日益普及，进一步增加了对有效治疗的需求。这一趋势，加上医疗保健服务水准的提高，正推动全球人体生长荷尔蒙市场持续扩张。此外，医护人员和大众对相关知识的普及也促使人们认识到解决这些生长迟缓的重要性，最终使荷尔蒙补充疗法得到更广泛的应用。

限制全球人体生长荷尔蒙市场的因素

由于有其他治疗生长迟缓的替代疗法，全球人体生长荷尔蒙市场面临挑战。非荷尔蒙疗法和生活方式调整提供了可行的选择，无需荷尔蒙干预即可达到类似的效果。因此，患者和医疗保健提供者可能更倾向于这些创伤性较小、价格通常更实惠的替代疗法。这种偏好的转变限制了对生长激素疗法的需求，并抑制了市场的成长潜力。因此，各种治疗方法的出现促使人们更加谨慎地使用生长激素，这成为市场格局中的一个主要阻碍因素。

全球人体生长荷尔蒙市场趋势

全球人体生长荷尔蒙市场正日益拥抱个人化治疗方案，这反映​​出个人化给药和给药技术的显着趋势。生物技术的进步使医疗专业人员能够根据患者的特定需求量身定制荷尔蒙疗法，从而优化治疗效果并改善患者的整体体验。这种个人化转变不仅提高了疗效，也有助于增强患者对治疗通讯协定的依从性。因此，在消费者对能够应对不同生理特征和独特健康挑战的个人化医疗解决方案的需求不断增长的推动下，该市场呈现出成长迹象，并有望最终改变荷尔蒙疗法的格局。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球人体生长荷尔蒙市场规模（按产品和复合年增长率划分）（2026-2033 年）

• 长效
• 其他的

全球人体生长荷尔蒙市场规模（按应用及复合年增长率划分）（2026-2033 年）

• 生长激素（GH）缺乏症
• 成人生长激素缺乏症
• 儿童生长激素缺乏症
• 透纳氏症
• 原发性矮小症
• 普拉德-威利症候群
• 胎龄偏矮
• 其他的

全球人体生长荷尔蒙市场规模（按分销管道和复合年增长率划分）（2026-2033 年）

• 医院药房
• 零售药房
• 网路药房
• 专科药房

全球人体生长荷尔蒙市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Novo Nordisk A/S（Denmark）
• Pfizer Inc.（USA）
• Eli Lilly and Company（USA）
• Merck KGaA（Germany）
• Genentech Inc.（USA）（Note：Part of the Roche Group）
• Ipsen SA（France）
• Ferring Pharmaceuticals（Switzerland）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Sandoz International GmbH（Germany）（Part of Novartis AG）
• Anhui Anke Biotechnology（Group）Co., Ltd.（China）
• GeneScience Pharmaceuticals Co., Ltd.（China）
• OPKO Health, Inc.（USA）
• Ascendis Pharma A/S（Denmark）
• EMD Serono Inc.（USA）（Part of Merck KGaA）
• F. Hoffmann-La Roche Ltd（Switzerland）
• Strongbridge Biopharma（USA）
• LG Life Sciences（South Korea）
• Biopartners GmbH（Germany）

结论与建议

Global Human Growth Hormone Market size was valued at USD 7.1 Billion in 2024 and is poised to grow from USD 7.97 Billion in 2025 to USD 20.17 Billion by 2033, growing at a CAGR of 12.3% during the forecast period (2026-2033).

The global human growth hormone market is experiencing robust expansion, driven by advancements in clinical guidelines for treating growth hormone deficiency and innovations in recombinant hormone therapies. Increased accessibility to treatments and heightened awareness of growth hormone insufficiency further propel this growth. Governments and health organizations promote early detection through awareness initiatives, underscoring the importance of addressing this condition. Major companies globally are investing in research and development to create growth hormones with fewer side effects, aligning with emerging market trends. Additionally, there is a concerted effort to effectively treat hormone-related conditions, as human growth hormone plays a vital role in processes like tissue regeneration and cell division, underscoring its significance in overall human growth and health management.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Human Growth Hormone market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Human Growth Hormone Market Segments Analysis

Global Human Growth Hormone Market is segmented by Product, Application, Distribution Channel and region. Based on Product, the market is segmented into Long Acting and Others. Based on Application, the market is segmented into Growth Hormone (GH) Deficiency, Adult GH Deficiency, Pediatric GH Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small For Gestational Age and Other. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy,Online Pharmacyand Specialty Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Human Growth Hormone Market

The rising incidence of irregular growth patterns, including conditions like Turner syndrome and growth hormone deficiency, significantly influences the global demand for human growth hormone products. As awareness of these conditions increases, earlier diagnosis becomes more common, thereby escalating the need for effective treatments. This trend, combined with improved healthcare access and services, further propels the expansion of the global human growth hormone market. Enhanced education among healthcare professionals and the public also contribute to recognizing the importance of addressing these growth disorders, ultimately leading to a greater emphasis on hormone replacement therapies.

Restraints in the Global Human Growth Hormone Market

The Global Human Growth Hormone market faces challenges due to the presence of alternative treatments for growth disorders. Non-hormonal therapies and lifestyle modifications offer viable options that may provide similar benefits without the need for hormone intervention. As a result, both patients and healthcare providers may prefer these less invasive and often more affordable alternatives. This shift in preference limits the demand for HGH therapies, hindering the growth potential of the market. Consequently, the emergence of various treatment modalities encourages a more cautious approach to HGH usage, creating a significant restraint in the overall market landscape.

Market Trends of the Global Human Growth Hormone Market

The global human growth hormone market is increasingly embracing personalized treatment approaches, reflecting a significant trend towards individualized dosing and delivery techniques. Advancements in biotechnology enable healthcare professionals to tailor growth hormone therapies to meet the specific needs of patients, optimizing therapeutic outcomes while enhancing the overall patient experience. This shift towards customization not only improves efficacy but also fosters stronger patient adherence to treatment protocols. As a result, the market is poised for growth, driven by the rising consumer demand for personalized healthcare solutions that cater to diverse physiological profiles and unique health challenges, ultimately transforming the landscape of growth hormone therapy.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Human Growth Hormone Market Size by Product & CAGR (2026-2033)

• Market Overview
• Long Acting
• Others

Global Human Growth Hormone Market Size by Application & CAGR (2026-2033)

• Market Overview
• Growth Hormone (GH) Deficiency
• Adult GH Deficiency
• Pediatric GH Deficiency
• Turner Syndrome
• Idiopathic Short Stature
• Prader-Willi Syndrome
• Small For Gestational Age
• Other

Global Human Growth Hormone Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Specialty Pharmacy

Global Human Growth Hormone Market Size & CAGR (2026-2033)

• North America (Product, Application, Distribution Channel)
  • US
  • Canada
• Europe (Product, Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Application, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech Inc. (USA) (Note: Part of the Roche Group)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH (Germany) (Part of Novartis AG)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anhui Anke Biotechnology (Group) Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeneScience Pharmaceuticals Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OPKO Health, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ascendis Pharma A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EMD Serono Inc. (USA) (Part of Merck KGaA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Strongbridge Biopharma (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LG Life Sciences (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biopartners GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations